Approval, reimbursement and pricing of high-cost cancer medicines in Australia

Por Vitry, Agnes
Publicado no J Pharm Policy Pract (2015)

Transparency is good, independence from pharmaceutical industry is better!

Por Vitry, Agnes
Publicado no Aust Prescr (2016)

Comparative assessment of four drug interaction compendia

Por Vitry, Agnes I
Publicado em 2007

Response to Michael Wonder’s comments on the article ‘Assessment of the therapeutic value of new medicines marketed in Australia’

Por Vitry, Agnes I
Publicado no J Pharm Policy Pract (2013)

Should the C in CME Stand for Commercial?

Por Lexchin, Joel, Vitry, Agnes
Publicado em 2012

Data informs debate

Por Gabb, Genevieve, Vitry, Agnes, Thynne, Tilenka
Publicado no Aust Prescr (2015)

Access to new cancer medicines in Australia: dispelling the myths and informing a public debate

Por Vitry, Agnes, Mintzes, Barbara, Lipworth, Wendy
Publicado no J Pharm Policy Pract (2016)

Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review

Por Othman, Noordin, Vitry, Agnes, Roughead, Elizabeth E.
Publicado em 2009

Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States

Por Othman, Noordin, Vitry, Agnes I, Roughead, Elizabeth E
Publicado em 2010

Medicines information in medical journal advertising in Australia, Malaysia and the United States: A comparative cross-sectional study

Por Othman, Noordin, Vitry, Agnes Isabelle, Roughead, Elizabeth Ellen
Publicado em 2010

Assessment of the therapeutic value of new medicines marketed in Australia

Por Vitry, Agnes I, Shin, Ng Huah, Vitre, Pauline
Publicado em 2013

Evaluating medication-related quality of care in residential aged care: a systematic review

Por Hillen, Jodie B, Vitry, Agnes, Caughey, Gillian E
Publicado no Springerplus (2015)

Prices of oncology medicines in European countries, Australia and New Zealand

Por Vogler, Sabine, Vitry, Agnes, Ud-Bin-Babar, Zaheer
Publicado no J Pharm Policy Pract (2015)

Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study

Por Vitry, Agnes, Nguyen, Tuan, Entwistle, Vikky, Roughead, Elizabeth
Publicado no J Pharm Policy Pract (2015)

Quality and availability of consumer information on heart failure in Australia

Por Vitry, Agnes I, Phillips, Susan M, Semple, Susan J
Publicado em 2008

Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity

Por Caughey, Gillian E, Tait, Kirsty, Vitry, Agnes I, Shakib, Sepehr
Publicado no Patient Prefer Adherence (2017)

Availability and prices of essential medicines for chronic diseases in older people in the Asia Pacific Region

Por Nguyen, Tuan A, Qiang, Sun, Wang, Haipeng, Undela, Krishna, Vitry, Agnes
Publicado no J Pharm Policy Pract (2015)

Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study

Por Ng, Huah Shin, Koczwara, Bogda, Roder, David, Niyonsenga, Theo, Vitry, Agnes
Publicado no J Comorb (2018)

Prevalence of comorbidity of chronic diseases in Australia

Por Caughey, Gillian E, Vitry, Agnes I, Gilbert, Andrew L, Roughead, Elizabeth E
Publicado em 2008

Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia

Por Othman, Noordin, Vitry, Agnes I, Roughead, Elizabeth E, Ismail, Shaiful B, Omar, Khairani
Publicado em 2010